Pubblicazioni 2012

n. linea

Progr. Linea Titolo Pubmed IF

GrezzoIF

Norm.

1 1

A convenient and robust in vivo reporter system to monitor gene expression in the human pathogen helicobacter pylori

"Vannini A, Agriesti F, Mosca F, Roncarati D, Scarlato V, Danielli A. A

3,829 6,00

1 2

A pilot characterization of human lung NSCLC by protein pathway activa-tion mapping

Zupa A, Improta G, Silvestri A, Pin E, Deng J, Aieta M, Musto P, Nitti D, Mammano E, Liotta L, Belluco C, Wulfkuhle J, Petricoin E 3rd. A pilot characterization of human lung NSCLC by protein pathway activation map-ping. J Thorac Oncol. 2012 Dec;7(12):1755-66. doi: 10.1097/JTO.0b013e3182725fc7. PubMed PMID: 23154546.

3,66 6,00

1 3

A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lym-phocytic leukemia

D’Arena G, D’Auria F, Simeon V, Laurenti L, Deaglio S, Mansueto G, DelPrincipe MI, Statuto T, Pietrantuono G, Gua-riglia R, Innocenti I, Martorelli MC, Villani O, De Feo V, Del Poeta G, Musto P. A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients withRai stage 0 chronic lymphocytic leukemia. Am J Hematol. 2012 Jun;87(6):628-31.doi: 10.1002/ajh.23170. Epub 2012 Mar 28. PubMed PMID: 22460620.

4,67 3,00

1 4

Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines

Piscazzi A, Costantino E, Maddalena F, Nata-licchio MI, Gerardi AM, AntonettiR, Cignarelli M, Landriscina M. Activation of the RAS/RAF/ERK signaling pathwaycontributes to resistance to sunitinib in thyroid carcinoma cell lines. J ClinEndocrinol Metab. 2012 Jun;97(6):E898-906. doi: 10.1210/jc.2011-3269. Epub 2012Mar 22. PubMed PMID: 22442268.

5,97 3,00

1 5

Anal metastasis from breast cancer: A case report and review of the literature

Bochicchio A, Tartarone A, Ignomirelli O, Latorre G, Cangiano R, Gallucci G, Coccaro M, Feudale E, Aieta M. Anal metastasis from breast cancer: a case report and review of the literature. Future Oncol. 2012 Mar;8(3):333-6. doi: 10.2217/fon.12.9. Review. PubMed PMID: 22409468.

3,16 4,00

1 6

Animal type melanoma: An unusual case with aggressive histological features?

Russo D, Vita G, Ilardi G, Siano M, Mascolo M. Animal type melanoma: an unusual case with aggressive histological features? Pathol Res Pract. 2012 Mar 15;208(3):169-71. doi: 10.1016/j.prp.2011.12.012. Epub 2012 Feb 5. PubMed PMID: 22309954.

1,21 2,00

1 7

Blastic plasmacytoid dendritic cell neoplasm with leukemic presenta-tion: an Italianmulticenter study.

Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C, Piccaluga PP, Di Bona E, Todisco E, Musto P, Spadea A, D’Arco A, Pileri S, Leone G, Amadori S, Facchetti F; GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell’A-dulto, Acute Leukemia Working Party). Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013 Feb;98(2):239-46. doi: 10.3324/haematol.2012.072645. Epub 2012 Oct 12. PubMed PMID: 23065521; PubMed Central PMCID: PMC3561431.

6,42 6,00

1 8

Bortezomib-thalidomi-de-dexamethasone is superior to thalidomi-de- dexamethasone as consolidation therapy after autologous hema-topoietic stem cell tran-splantation in patients with newly diagnosed multiple myeloma

Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, CrippaC, Boccadoro M, Perrone G, Falcone A, Noz-zoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Ita-liano Malattie Ematologiche dell’Adulto) Italian Myeloma Network. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplan-tation in patients with newly diagnosed multiple myeloma. Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12. PubMed PMID: 22498745.

9,90 8,00

1 9

Cardiovascular events and intensity of tre-atment in polycythemia vera

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8. PubMed PMID: 23216616.

53,30 15,00

1 10

Chronic lymphocytic leukemia after chro-nic myeloid leukemia in the same patient: Two different genomic events and a common treatment?

D’Arena G, Gemei M, Luciano L, D’Auria F, Deaglio S, Statuto T, Bianchino G, Grieco V, Man-sueto G, Guariglia R, Pietrantuono G, Martorelli MC, Villani O, Del Vecchio L, Musto P. Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different ge-nomic events and a common treatment? J Clin Oncol. 2012 Nov 10;30(32):e327-30. doi: 10.1200/JCO.2012.42.6767. Epub 2012 Sep24. PubMed PMID: 23008321.

18,37 15,00

1 11

Cisplatin and 5-fluo-rouracil in inoperable, stage IV squamous cell carcinoma of the penis

Di Lorenzo G, Buonerba C, Federico P, Perdonà S, Aieta M, Rescigno P, D’Aniello C, Puglia L, Petremolo A, Ferro M, Marinelli A, Palmieri G, Sonpavde G, Mirone V, De Placido S. Cisplatin and 5-fluorouracil in inoperable, stage IV squa-mous cell carcinoma of the penis. BJU Int. 2012 Dec;110(11 Pt B):E661-6. doi: 10.1111/j.1464-410X.2012.11453.x. Epub 2012 Sep 10. PubMed PMID: 22958571.

2,84 6,00

1 12

Design and characte-rization of a peptide mimotope of the HIV-1 gp120 bridging sheet

Schiavone M, Fiume G, Caivano A, de Lauren-tiis A, Falcone C, Masci FF, Iaccino E, Mimmi S, Palmieri C, Pisano A, Pontoriero M, Rossi A, Scialdone A, Vecchio E, Andreozzi C, Trovato M, Rafay J, Ferko B, Montefiori D, Lombardi A, Mor-sica G, Poli G, Quinto I, Pavone V, de Berardinis P, Scala G. Design and Characterizationof a Peptide Mimotope of the HIV-1 gp120 Bridging Sheet. Int J Mol Sci.2012;13(5):5674-99. doi: 10.3390/ijms13055674. Epub 2012 May 10. PubMed PMID: 22754323; PubMed Central PMCID: PMC3382813.

2,60 3,00

1 13

Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome

Rossi D, Rasi S, Spina V, Fangazio M, Monti S, Greco M, Ciardullo C, Famà R,Cresta S, Bruscaggin A, Laurenti L, Martini M, Musto P, Forconi F, Marasca R,Larocca LM, Foà R, Gaidano G. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transfor-mation to Richter syndrome. Br J Haematol. 2012 Aug;158(3):426-9. doi: 10.1111/j.1365-2141.2012.09155.x. Epub 2012 May 10. PubMed PMID: 22571487.

4,94 3,00

1 14

Dynamic changes of live/apoptotic circulating tumour cells as predic-tive marker of response to Sunitinib in metasta-tic renal cancer

Rossi E, Fassan M, Aieta M, Zilio F, Celadin R, Borin M, Grassi A, Troiani L, Basso U, Barile C, Sava T, Lanza C, Miatello L, Jirillo A, Rugge M, Indraccolo S, Cristofanilli M, Amadori A, Zamarchi R. Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. Br J Cancer. 2012 Oct 9;107(8):1286-94. doi: 10.1038/bjc.2012.388. Epub 2012 Sep 6. PubMed PMID: 22955853; PubMed Central PMCID: PMC3494437.

5,04 3,00

1 15

Effect of Acute Lung Injury on VLA-4 and CXCR4 Expression in Resident and Circulating Hematopoietic Stem/Progenitor Cells.

Trotta T, Di Gioia S, Piro D, Lepore S, Cantatore S, Porro C, Castellani S, Petrella A, Fortunato F, Maffione AB, Conese M. Effect of acute lung injury on VLA-4 and CXCR4 expression in resident and circulating hematopoieticstem/progenitor cells. Respiration. 2013;85(3):252-64. doi: 10.1159/000341172.Epub 2012 Sep 26. PubMed PMID: 23018206.

2,26 1,00

1 16

Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma

Corazzelli G, Angrilli F, D’Arco A, Ferrara F, Musto P, Guarini A, Cox MC, Stelitano C, Storti S, Iannitto E, Falorio S, Califano C, Amore A, Arcamone M, De Filippi R, Pinto A. Efficacy and safety of bendamustine for the treatment ofpatients with recurring Hodgkin lymphoma. Br J Haematol. 2013 Jan;160(2):207-15. doi: 10.1111/bjh.12120. Epub 2012 Nov 20. PubMed PMID: 23167437.

4,94 6,00

1 17

Efficacy of bortezomib in systemic extrame-dullary localizations of multiple myeloma

Federico V, Breccia M, Petrucci MT, Loglisci G, Mansueto G, Mercanti C, LeviA, Cartoni C, Musto P, Alimena G. Efficacy of bortezomib in systemicextramedullary localizations of multiple myelo-ma. Clin Adv Hematol Oncol. 2012Apr;10(4):266-8. PubMed PMID: 22706491.

0,00 0,10

1 18

Efficacy of bortezo-mib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.

Gozzetti A, Musto P, Defina M, D’Auria F, Papini G, Statuto T, D’Arena G, Bocchia M. Efficacy of bortezomib, lenalidomide and dexamethaso-ne (VRD) in secondary plasma cell leukaemia. Br J Haematol. 2012 May;157(4):497-8. doi: 10.1111/j.1365-2141.2012.09029.x. Epub 2012 Feb 1. Erratum in: Br J Haematol. 2012 Aug;158(3):430. Steduto, Teodora [corrected to Statuto, Teodora]. PubMed PMID: 22296516.

4,94 3,00

1 19Everolimus in HR-po-sitive advanced breast cancer

Tartarone A, Lerose R, Aieta M. Everolimus in HR-positive advanced breastcancer. N Engl J Med. 2012 May 3;366(18):1739; author reply 1739-40. doi:10.1056/NEJMc1202719#SA2. PubMed PMID: 22551140.

53,30 0,00

1 20

Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with chan-ges in transcriptional profiles

Mosca L, Musto P, Todoerti K, Barbieri M, Agnelli L, Fabris S, Tuana G, Lionetti M, Bonaparte E, Sirchia SM, Grieco V, Bianchino G, D’Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Caravita T, Omedè P, Boccadoro M, Palumbo A, Neri A. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imba-lances associated with changes in transcriptional profiles. Am J Hematol. 2013 Jan;88(1):16-23. doi: 10.1002/ajh.23339. Epub 2012 Oct 9. PubMed PMID: 23044976.

4,67 6,00

1 21

Hight rate of remissions in chronic myelomo-nocytic leukemia trea-ted with 5-azacytidine: results of an Italian retrospective study.

Fianchi L, Criscuolo M, Breccia M, Maurillo L, Salvi F, Musto P, Mansueto G, Gaidano G, Finelli C, Aloe-Spiriti A, Santini V, Greco M, Hohaus S, Leone G, Voso MT. High rate of remissions in chronic myelomonocytic leukemia treated with5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma. 2013 Mar;54(3):658-61. doi: 10.3109/10428194.2012.719617. Epub 2012 Aug 30. PubMed PMID: 22873829.

2,58 2,00

1 22How to distinguish an active air leak from a pleural space effect

Marasco RD, Giudice G, Lequaglie C. How to distinguish an active air leak from a pleural space effect. Asian Cardiovasc Thorac Ann. 2012 Dec;20(6):682-8. doi: 10.1177/0218492312451918. PubMed PMID: 23284110.

0,00 0,10

1 23

Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC

Zupa A, Vita G, Landriscina M, Possidente L, Aieta M, Tartarone A, Improta G. Identifica-tion of a new insertion in exon 20 of EGFR in a woman with NSCLC. Med Oncol. 2012 Dec;29(5):3198-201. doi: 10.1007/s12032-012-0304-y. Epub 2012 Jul 8. PubMed PMID: 22773041.

2,14 2,00

1 24

IGHV gene mutational status and 17p deletion are independent mo-lecular predictors in a comprehensive clinical-biological prognostic model for overall survi-val prediction in chronic lymphocytic leukemia

Bulian P, Rossi D, Forconi F, Del Poeta G, Bertoni F, Zucca E, Montillo M, Pozzato G, D’Arena G, Efremov DG, Marasca R, Lauria F, Gaidano G, Gattei V, Laurenti L. IGHV gene mutational status and 17p deletion are independentmolecular predictors in a comprehensive clinical-biological prognostic model for ove-rall survival prediction in chronic lymphocytic leukemia. J Transl Med. 2012 Jan 30;10:18. doi: 10.1186/1479-5876-10-18. PubMed PMID: 22289136; PubMed Central PMCID: PMC3297493.

3,47 3,00

1 25

Impact of BCR-ABL mutations on response to dasatinib after ima-tinib failure in elderly patients with chronic-phase chronic myeloid leukemia.

Tiribelli M, Latagliata R, Luciano L, Castagnetti F, Gozzini A, Cambrin GR, Annunziata M, Stagno F, Pregno P, Albano F, Abruzzese E, Musto P, Montefusco E, Fava C, Fanin R, Pane F, Rosti G, Breccia M, Alimena G, Vigneri P. Impact ofBCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. Ann Hematol. 2013 Jan;92(2):179-83. doi: 10.1007/s00277-012-1591-2. Epub 2012 Oct 10. PubMed PMID: 23053188.

2,62 4,00

1 26

Intraosseous lipoma of the skull base, involving the sphenoclival region: Case report

Solari D, Angel VF, Barcelò SR, Napoli M, Vita G, Lombardi L, Cavallo LM, Cappabianca P. Intra-osseous lipoma of the skull base, involving the sphenoclival region: case report. Clin Neurol Neurosurg. 2012 Dec;114(10):1368-70. Doi:10.1016/j.clineuro.2012.03.030. Epub 2012 Apr 18. PubMed PMID: 22516414.

1,58 2,00

1 27

Lenalidomide cutaneous adverse event: A case of Stevens-Johnson syn-drome (SJS) in a prima-ry plasma cell leukaemia patient treated with lenalidomide and dexa-methasone

Siniscalchi A, Tendas A, Morino L, Dentamaro T, De Bellis A, Perrotti A, de Fabritiis P, Musto P, Caravita T. Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone. Support Care Cancer. 2012 Jul;20(7):1585-7. doi: 10.1007/s00520-012-1481-0. Epub 2012 May 5. PubMed PMID: 22562584.

2,60 3,00

1 28

Lenalidomide-predni-sone induction follo-wed by lenalidomide-melphalan-prednisone consolidation and le-nalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients

Falco P, Cavallo F, Larocca A, Rossi D, Gugliel-melli T, Rocci A, Grasso M, Siez ML, De Paoli L, Oliva S, Molica S, Mina R, Gay F, Benevolo G, Musto P, Omedè P, Freilone R, Bringhen S, Carel-la AM, Gaidano G, Boccadoro M, Palumbo A.Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolida-tion and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma pa-tients. Leukemia. 2013 Mar;27(3):695-701. doi:10.1038/leu.2012.271. Epub 2012 Sep 21. PubMed PMID: 22996335.

9,56 8,00

1 29

Long-term survival in patients with metastatic breast cancer receiving intensified chemo-therapy and stem cell rescue: data from the Italian registry

Martino M, Ballestrero A, Zambelli A, Secondino S, Aieta M, Bengala C,Liberati AM, Zamagni C, Musso M, Aglietta M, Schiavo R, Castagna L, Rosti G, Bruno B, Pedrazzoli P. Long-term sur-vival in patients with metastatic breastcancer receiving intensified chemothe-rapy and stem cell rescue: data from theItalian registry. Bone Marrow Transplant. 2013 Mar;48(3):414-8. doi: 10.1038/bmt.2012.149. Epub 2012 Aug 6. PubMed PMID: 22863724.

3,75 6,00

1 30

Loss of MUTYH fun-ction in human cells leads to accumulation of oxidative damage and genetic instability.

Ruggieri V, Pin E, Russo MT, Barone F, Degan P, Sanchez M, Quaia M, MinoprioA, Turco E, Mazzei F, Viel A, Bignami M. Loss of MUTYH function in human cellsleads to accumulation of oxidative da-mage and genetic instability. Oncogene. 2012 Oct 29. doi: 10.1038/onc.2012.479. [Epub ahead of print] PubMed PMID: 23108399.

6,37 6,00

1 31

Malignant dermatofi-broma: clinicopatholo-gical, immunohistoche-mical, and molecular analysis of seven cases

Mentzel T, Wiesner T, Cerroni L, Hantsch-ke M, Kutzner H, Rütten A, Häberle M, Bisceglia M, Chibon F, Coindre JM. Mali-gnant dermatofibroma: clinicopathologi-cal, immunohistochemical, and molecular analysis of seven cases. Mod Pathol. 2013Feb;26(2):256-67. doi: 10.1038/modpa-thol.2012.157. Epub 2012 Sep 21. PubMed PMID: 22996372.

4,79 3,00

1 32

Mast cell sarcoma of the scalp: The first sign of undisclosed systemic mastocytosis?

Falleti J, Borgia L, Lalinga AV, De Cecio R, Natella V, Patitucci G, Vita G.Mast cell sarcoma of the scalp: the first sign of undisclosed systemicmastocytosis? Pathol Res Pract. 2012 Nov 15;208(11):683-6. doi:10.1016/j.prp.2012.06.010. Epub 2012 Sep 7. PubMed PMID: 22963840.

1,21 2,00

1 33Modification of QRS pattern in a patient with AL amyloidosis

Gallucci G, Guariglia R, Cangiano R, Man-sueto G, Martorelli MC, Musto P.Modification of QRS pattern in a patient with AL amyloidosis. Int J Cardiol. 2013Apr 5;164(2):e9-e12. doi: 10.1016/j.ijcard.2012.09.146. Epub 2012 Oct 9. PubMed PMID: 23058354.

7,08 4,00

1 34New insights into TRAP1 pathway

Matassa DS, Amoroso MR, Maddalena F, Landriscina M, Esposito F. New insightsinto TRAP1 pathway. Am J Cancer Res. 2012;2(2):235-48. Epub 2012 Feb 19. PubMed PMID: 22432061; PubMed Cen-tral PMCID: PMC3304566.

0,00 0,10

1 35

Newly proposed therapy-related mye-lodysplastic syndro-me prognostic score predicts significant differences in verall survival and leukemia-free survival in patients treated with azacitidine

Breccia M, Fianchi L, Lunghi M, Gaidano G, Levis A, Finelli C, Santini V,Musto P, Mansueto G, Oliva EN, Le-oni P, Spiriti MA, Hohaus S, Leone G, Alimena G, Voso MT. Newly proposed therapy-related myelodysplastic syn-drome prognostic score predicts signi-ficant differences in overall survival and leukemia-free survival in patients treated with azacitidine. Leuk Lymphoma. 2012 Dec 10. [Epub ahead of print] PubMed PMID: 23151268.

2,58 2,00

1 36

Outcome of therapy-related myeloid neo-plasms treated with azacitidine

Fianchi L, Criscuolo M, Lunghi M, Gaida-no G, Breccia M, Levis A, Finelli C,Santini V, Musto P, Oliva EN, Leoni P, Aloe Spiriti A, D’Alò F, Hohaus S, Pagano L, Leone G, Voso MT. Outcome of the-rapy-related myeloid neoplasms treated with azacitidine. J Hematol Oncol. 2012 Aug 1;5:44. doi: 10.1186/1756-8722-5-44. PubMed PMID: 22853048; PubMed Central PMCID: PMC3419605.

3,99 6,00

1 38

PPARs and HCV-related hepatocarcinoma: A mitochondrial point of view

Agriesti F, Tataranni T, Ruggieri V, Capita-nio N, Piccoli C. PPARs andHCV-Related Hepatocarcinoma: A Mito-chondrial Point of View. PPAR Res.2012;2012:605302. doi: 10.1155/2012/605302. Epub 2012 Aug 16. PubMed PMID:22966221; PubMed Central PMCID: PMC3431172.

1,56 2,00

1 39

Reactive oxygen species regulate the levels of dual oxidase (duox1-2) in human neuroblasto-ma cells

Damiano S, Fusco R, Morano A, De Mi-zio M, Paternò R, De Rosa A, Spinelli R,Amente S, Frunzio R, Mondola P, Miot F, Laccetti P, Santillo M, Avvedimento EV. Reactive oxygen species regulate the levels of dual oxidase (Duox1-2) in human neuroblastoma cells. PLoS One. 2012;7(4):e34405. doi: 10.1371/journal.pone.0034405. Epub 2012 Apr 16. PubMed PMID: 22523549; PubMed Central PMCID: PMC3327694.

4,09 3,00

1 40Reflections about off-label use of anticancer drugs

Tartarone A, Lerose R, Aieta M. Reflec-tions about off-label use of anticancer drugs. Ther Drug Monit. 2012 Oct;34(5):604. doi: 10.1097/FTD.0b013e318268478d.PubMed PMID: 22972541.

2,49 3,00

1 41

Regulatory T-Cells in Chronic Lymphocytic Leukemia and Autoim-mune Diseases.

D’Arena G, Rossi G, Vannata B, Deaglio S, Mansueto G, D’Auria F, Statuto T,Simeon V, De Martino L, Marandino A, Del Poeta8 G, De Feo V, Musto P. Regulatory T-Cells in Chronic Lym-phocytic Leukemia and Autoimmune Diseases. Mediterr J Hematol Infect Dis. 2012;4(1):e2012053. Epub 2012 Aug 9. PubMed PMID: 22973497; PubMed Central PMCID: PMC3435126.

0,00 0,10

1 42

Role of the common γ chain in cell cycle progression of human malignant cell lines

Vigliano I, Palamaro L, Bianchino G, Fusco A, Vitiello L, Grieco V, Romano R, Salvatore M, Pignata C. Role of the com-mon γ chain in cell cycle progression ofhuman malignant cell lines. Int Immunol. 2012 Mar;24(3):159-67. doi:10.1093/intimm/dxr114. Epub 2012 Jan 5. PubMed PMID: 22223761.

3,42 2,00

1 43

Sanger sequencing in routine KRAS testing: A review of 1720 cases from a pathologist's perspective

Malapelle U, Bellevicine C, Salatiello M, de Luca C, Rispo E, Riccio P, Sparano L, De Stefano A, Carlomagno C, Maiello FM, Vita G, Nappi O, Troncone G.Sanger sequencing in routine KRAS te-sting: a review of 1720 cases from apathologist’s perspective. J Clin Pathol. 2012 Oct;65(10):940-4. Epub 2012 Aug 7. PubMed PMID: 22872705; PubMed Central PMCID: PMC3461636.

2,31 4,00

1 44

Symplastic glomus tumor: Report of a challenging lesion with literature review

Falleti J, Vita G, De Cecio R, Schonauer F, Insabato L, Natella V, Mascolo M. Sym-plastic glomus tumor: report of a chal-lenging lesion with literature review.Pathol Res Pract. 2012 Jun 15;208(6):372-5. doi: 10.1016/j.prp.2012.04.001. Epub 2012 May 7. Review. PubMed PMID: 22572036.

1,21 2,00

1 45

Synchronous adenocar-cinoma, squamocellular carcinoma, and bron-chioloalveolar carcino-ma in the same pulmo-nary lobe

Garramone M, Giudice G, Marasco R, Lequaglie C. Synchronous adenocarci-noma, squamocellular carcinoma, and bronchioloalveolar carcinoma in the same pulmonary lobe. Eur J Clin Med Oncol. 2012; 4 (3): 59.

0,00 0,10

1 46Targeting mitochondria in the infection strategy of the hepatitis C virus

Quarato G, Scrima R, Agriesti F, Mo-radpour D, Capitanio N, Piccoli C.Targeting mitochondria in the infection strategy of the hepatitis C virus. Int J Biochem Cell Biol. 2013 Jan;45(1):156-66. doi: 10.1016/j.biocel.2012.06.008. Epub 2012 Jun 16. PubMed PMID: 22710347.

4,63 3,00

1 47

The cardiovascular risk of gonadotropin relea-sing hormone agonists in men with prostate cancer: An unresolved controversy

Conteduca V, Di Lorenzo G, Tartarone A, Aieta M. The cardiovascular risk ofgonadotropin releasing hormone ago-nists in men with prostate cancer: anunresolved controversy. Crit Rev Oncol Hematol. 2013 Apr;86(1):42-51. doi:10.1016/j.critrevonc.2012.09.008. Epub 2012 Oct 23. PubMed PMID: 23092636.

4,41 6,00

1 48

The PD-1/PD-L1 axis contributes to T cell dysfunction in chronic lymphocytic leukemia.

Brusa D, Serra S, Coscia M, Rossi D, D’A-rena G, Laurenti L, Jaksic O, FedeleG, Inghirami G, Gaidano G, Malavasi F, Deaglio S. The PD-1/PD-L1 axis con-tributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013 Jun;98(6):953-63. doi: 10.3324/haematol.2012.077537. Epub 2013 Jan 8. PubMed PMID: 23300177; PubMed Central PMCID: PMC3669453.

6,42 3,00

1 49

Use of a sealant to pre-vent prolonged air leaks after lung resection: a prospective randomized study

Lequaglie C, Giudice G, Marasco R, Mor-te AD, Gallo M. Use of a sealant toprevent prolonged air leaks after lung re-section: a prospective randomized study.J Cardiothorac Surg. 2012 Oct 8;7:106. doi: 10.1186/1749-8090-7-106. PubMed PMID: 23043755; PubMed Central PMCID: PMC3508954.

1,19 2,00

1 50

Using rHuG-CSF in multiple myeloma: Con-solidated data, Evolu-tions, and new concepts

Musto P. Using rHuG-CSF in multiple myeloma: Consolidated data, Evolu-tions, and new concepts. Milestones in Drug Therapy. 2012; 43: 211-223. doi: 10.1007/978-3-0348-0218-5.

0,00 0,10

1 51What is better for older patients with acute myeloid leukemia?

Ferrara F, Musto P. What is better for older patients with acute myeloidleukemia? J Clin Oncol. 2013 Feb 20;31(6):820-1. doi: 10.1200/JCO.2012.45.2219. Epub 2012 Nov 5. PubMed PMID: 23129743.

18,37 7,50

Totale Pubblicazioni n. 51 306,88 196,10

2 1

Alcohol drinking and endometrial cancer risk in the European Pro-spective Investigation into Cancer and Nutri-tion (EPIC) study

Fedirko V, Jenab M, Rinaldi S, Biessy C, Allen NE, Dossus L, Onland-Moret NC, Schütze M, Tjønneland A, Hansen L, Overvad K, Clavel-Chapelon F, Chabbert-Buffet N, Kaaks R, Lukanova A, Bergmann MM, Boeing H, Trichopoulou A, Oustoglou E, Barbitsioti A, Saieva C, Tagliabue G, Galasso R, Tumino R, Sacerdote C, Peeters PH, Bueno-de-Mesquita HB, Weiderpass E, Gram IT, Sanchez S, Duell EJ, Molina-Montes E, Arriola L, Chirlaque MD, Ardanaz E, Manjer J, Lundin E, Idahl A, Khaw KT, Romaguera-Bosch D, Wark PA, Norat T, Romieu I. Alcohol drinking and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Ann Epidemiol. 2013 Feb;23(2):93-8. Doi: 10.1016/j.annepidem.2012.11.009. Epub 2012 Dec 25. PubMed PMID: 23273691.

3,22 6,00

2 2

Coffee and tea con-sumption and the risk of ovarian cancer: A prospective cohort stu-dy and updated meta-analysis

Braem MG, Onland-Moret NC, Schouten LJ, Tjønne-land A, Hansen L, Dahm CC, Overvad K, Lukanova A, Dossus L, Floegel A, Boeing H, Clavel-Chapelon F, Chabbert-Buffet N, Fagherazzi G, Trichopoulou A, Benetou V, Goufa I, Pala V, Galasso R, Mattiello A, Sacerdote C, Palli D, Tumino R, Gram IT, Lund E, Gavrilyuk O, Sánchez MJ, Quirós R, Gonzales CA, Dorronsoro M, Castaño JM, Gurrea AB, Idahl A, Ohlson N, Lundin E, Jirstrom K, Wirfalt E, Allen NE, Tsilidis KK, Kaw KT, Bueno-de-Mesquita HB, Dik VK, Rinaldi S, Fedirko V, Norat T, Riboli E, Kaaks R, Peeters PH. Coffee and tea consumption and the risk of ovarian cancer: a prospective cohort study and updated meta-analysis. Am J Clin Nutr. 2012 May;95(5):1172-81. Doi: 10.3945/ajcn.111.026393. Epub 2012 Mar 21. PubMed PMID: 22440851.

6,67 6,00

2 3Errors in the radiolo-gical evaluation of the alimentary tract: part I.

Mandato Y, Reginelli A, Galasso R, Iacobellis F, Berrit-to D, Cappabianca S. Errors in the radiological eva-luation of the alimentary tract: part I. Semin Ultra-sound CT MR. 2012 Aug;33(4):300-7. doi: 10.1053/j.sult.2012.01.011. PubMed PMID: 22824120.

1,24 1,00

2 4

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chro-nic myelogenous leukaemia. Hematol Oncol. 2013 Jun;31(2):363-9. doi: 10.1002/hon.2020. Epub 2012 Jul 19. PubMed PMID: 22815278.

2,48 4,00

2 5Lifestyle and breast cancer recurrences: The DIANA-5 trial

Villarini A, Pasanisi P, Traina A, Mano MP, Bonanni B, Panico S, Scipioni C, Galasso R, Paduos A, Simeoni M, Bellotti E, Barbero M, Macellari G, Venturelli E, Raimondi M, Bruno E, Gargano G, Fornaciari G, Morelli D, Seregni E, Krogh V, Berrino F. Life-style and breast cancer recurrences: the DIA-NA-5 trial. Tumori. 2012 Jan-Feb;98(1):1-18. doi: 10.1700/1053.11494. PubMed PMID: 22495696.

0,61 1,00

2 6

Multiple miscarriages are associated with the risk of ovarian cancer: Results from the eu-ropean prospective investigation into cancer and nutrition

Braem MG, Onland-Moret NC, Schouten LJ, Kruitwa-gen RF, Lukanova A, Allen NE, Wark PA, Tjønneland A, Hansen L, Braüner CM, Overvad K, Clavel-Chapelon F, Chabbert-Buffet N, Teucher B, Floegel A, Boeing H, Trichopoulou A, Adarakis G, Plada M, Rinaldi S, Fedirko V, Romieu I, Pala V, Galasso R, Sacerdote C, Palli D, Tu-mino R, Bueno-de-Mesquita HB, Gram IT, Gavrilyuk O, Lund E, Sánchez MJ, Bonet C, Chirlaque MD, Larraña-ga N, Gurrea AB, Quirós JR, Idahl A, Ohlson N, Lundin E, Jirström K, Butt S, Tsilidis KK, Khaw KT, Wareham N, Riboli E, Kaaks R, Peeters PH. Multiple miscarriages are associated with the risk of ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition. PLoS One. 2012;7(5):e37141. doi: 10.1371/journal.pone.0037141. Epub 2012 May 18. PubMed PMID: 22623987; PubMed Central PMCID: PMC3356371.

4,09 3,00

2 7

Quality of life and physi-cians' perception in myelodisplastic syndro-mes.

Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, Impera S, Terenzi A, Levis A, Cortelezzi A, Ghio R, Musto P, Semenzato G, Clissa C, Lunghi T,Trappolini S, Gaidano V, Salvi F, Reda G, Villani O, Binotto G, Cufari P, Cavalieri E, Spiriti MA. Quality of life and physicians’ perception in myelodysplastic syndromes. Am J Blood Res. 2012;2(2):136-47. Epub 2012 May 25. PubMed PMID: 22762033; PubMed Central PMCID: PMC3384400.

0,10

2 8

The postoperative analgesic efficacy of preperitoneal conti-nuous wound infusion compared to epidural continuous infusion with local anesthetics after colorectal cancer surgery: A randomized controlled multicenter study

Bertoglio S, Fabiani F, Negri PD, Corcione A, Merlo DF, Cafiero F, Esposito C, Belluco C, Pertile D, Amodio R, Mannucci M, Fontana V, Cicco MD, Zappi L. The postoperative analgesic efficacy of preperitoneal continuous wound infusion com-pared to epidural continuous infusion with local anesthetics after colorectal cancer surgery: a randomized controlled multicenter study. Anesth Analg. 2012 Dec;115(6):1442-50. doi: 10.1213/ANE.0b013e31826b4694. Epub 2012 Nov 9. PubMed PMID: 23144438.

3,29 6,00

2 9

The retroangular flap in facial reconstruction: The exhaustive point of view

Fabrizio T, Tassinari J, Mori A, Orlan-dino G. The retroangular flap in facial reconstruction: the exhaustive point of view. Plast Reconstr Surg. 2012 Mar;129(3):567e-568e. Doi: 10.1097/PRS.0b013e3182419b2f. PubMed PMID: 22374021.

3,38 3,00

Totale Pubblicazioni n.9 24,97 30,10

3 1

A National project for in vivo dosimetry pro-cedures in radiotherapy: First results

Piermattei A, Greco F, Azario L, Porcelli A, Zucca S, Russo A, Castro E, Russo M, Caivano R, Fusco V, Morganti A, Fidanzio A. A National project for in vivo dosime-try procedures in radiotherapy: First re-sults. Nucl Instrum Meth B. 274 (2012); 42-50. doi:10.1016/j.nimb.2011.12.004.

1,21 4,00

3 2

A new model for pre-dicting acute mucosal toxicity in head-and-neck cancer patients undergoing radio-therapy with altered schedules

Strigari L, Pedicini P, D’Andrea M, Pinnarò P, Marucci L, Giordano C, Benassi M. A new model for predicting acute mucosal toxicity in head-and-neck cancer patients undergoing radiotherapy with altered schedules. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e697-702. doi: 10.1016/j.ijrobp.2012.02.004. Epub 2012 May 10. Review. PubMed PMID: 22578541.

4,11 6,00

3 3

Adjuvant radiochemo-therapy in the elderly affected by glioblastoma: single-institution expe-rience and literature review

Fiorentino A, Chiumento C, Caivano R, Cozzolino M, Pedicini P, Fusco V. Adju-vant radiochemotherapy in the elderly affected by glioblastoma:single-institution experience and lite-rature review.. Radiol Med. 2012 Nov 26. Epub ahead of print Italian. PubMed PMID: 23184248.

1,44 2,00

3 4

Comorbidity asses-sment and adjuvant radiochemotherapy in elderly affected by glioblastoma

Fiorentino A, Caivano R, Chiumento C, Cozzolino M, Clemente S, Pedicini P, Fusco V. Comorbidity assessment and adjuvant radiochemotherapy in elderly affected by glioblastoma. Med Oncol. 2012 Dec;29(5):3467-71. Doi: 10.1007/s12032-012-0246-4. Epub 2012 May 12. PubMed PMID: 22580816.

2,14 2,00

3 5

Comparative dosime-tric and radiobiological assessment among a nonstandard RapidArc, standard RapidArc, classical intensity-mo-dulated radiotherapy, and 3D brachytherapy for the treatment of the vaginal vault in patients affected by gynecologic cancer

Pedicini P, Caivano R, Fiorentino A, Striga-ri L, Califano G, Barbieri V,Sanpaolo P, Castaldo G, Benassi M, Fusco V. Comparative dosimetric andradiobiological assessment among a non-standard RapidArc, standard RapidArc,classical intensity-modulated radiothe-rapy, and 3D brachytherapy for thetreatment of the vaginal vault in patients affected by gynecologic cancer. MedDosim. 2012 Winter ;37(4):347-52. doi: 10.1016/j.meddos.2011.11.009. Epub 2012 Mar 3. PubMed PMID: 22382087.

1,00 1,00

3 6

Cone-beam computed tomography dose mo-nitoring during intensi-ty-modulated radiothe-rapy in head and neck cancer: parotid glands

Fiorentino A, Cozzolino M, Caivano R, Pedicini P, Chiumento C, Oliviero C,Clemente S, Fusco V. Cone-beam com-puted tomography dose monitoring during intensity-modulated radiotherapy in head and neck cancer: parotid glands. Clin Transl Oncol. 2013 May;15(5):412-5. doi: 10.1007/s12094-012-0946-4. Epub 2012 Oct 13. PubMed PMID: 23065602.

1,33 1,00

3 7

Correlation between egfr expression and ac-celerated proliferation during radiotherapy of head and neck squa-mous cell carcinoma

Pedicini P, Nappi A, Strigari L, Jereczek-Fossa BA, Alterio D, Cremonesi M,Botta F, Vischioni B, Caivano R, Fiorentino A, Improta G, Storto G, Benassi M,Orecchia R, Salvatore M. Correlation between EGFr expression and accelera-ted proliferation during radiotherapy of head and neck squamous cell carcinoma.Radiat Oncol. 2012 Aug 24;7:143. doi: 10.1186/1748-717X-7-143. Review. PubMed PMID: 22920680; PubMed Cen-tral PMCID: PMC3537603.

2,32 4,00

3 8

Elderly patients affected by glioblastoma treated with radiotherapy: the role of serum hemoglo-bin level.

Fiorentino A, Fusco V. Elderly patients affected by glioblastoma treated with radiotherapy: the role of serum hemo-globin level. Int J Neurosci. 2013Feb;123(2):133-7. doi: 10.3109/00207454.2012.744309. Epub 2012 Dec 6. PubMedPMID: 23110493.

0,97 1,00

3 9 Elderly people with glioblastoma

Fiorentino A, Balducci M, Chiesa S, Fusco V. Elderly people with glioblastoma.Lancet Oncol. 2012 Aug;13(8):e327-8; author reply e329. doi: 10.1016/S1470-2045(12)70276-0. PubMed PMID: 22846834.

22,59 7,50

3 10Ewing sarcoma of the thoracic wall in a 54-year-old man

Fiorentino A, Chiumento C, Caivano R, Fusco V. Ewing sarcoma of the thoracicwall in a 54-year-old man. Tumo-ri. 2012 Jan-Feb;98(1):e10-2. doi: 10.1700/1053.11522. PubMed PMID: 22495722.

0,61 1,00

3 11Low-dose rate brachy-therapy of the prostate in elderly patients

Chiumento C, Fiorentino A, Caivano R, Clemente S, Fusco V. Low-dose ratebrachytherapy of the prostate in el-derly patients. Radiol Med. 2012 Sep 17. [Epub ahead of print] PubMed PMID: 22986692.

1,44 2,00

3 12

Modelling the corre-lation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and mono-clonal antibody EGFr inhibitors

Pedicini P, Caivano R, Jereczek-Fossa BA, Strigari L, Vischioni B, Alterio D, Cremonesi M, Botta F, Nappi A, Improta G, Storto G, Benassi M, Orecchia R.Modelling the correlation between EGFr expression and tumour cellradiosensitivity, and combined tre-atments of radiation and monoclonal antibody EGFr inhibitors. Theor Biol Med Model. 2012 Jun 19;9:23. doi:10.1186/1742-4682-9-23. PubMed PMID: 22713695; PubMed Central PMCID: PMC3502488.

1,86 4,00

3 13

Parotid gland volume-tric changes during intensity-modulated radiotherapy in head and neck cancer

Fiorentino A, Caivano R, Metallo V, Chiu-mento C, Cozzolino M, Califano G,Clemente S, Pedicini P, Fusco V. Parotid gland volumetric changes duringintensity-modulated radiotherapy in head and neck cancer. Br J Radiol. 2012Oct;85(1018):1415-9. doi: 10.1259/bjr/30678306. Epub 2012 May 9. PubMed PMID: 22573295; PubMed Cen-tral PMCID: PMC3474039.

1,31 2,00

3 14

Patients younger than 40years old and ol-der than 70years old affected by ER(-)/PR(-)/HER2(-) breast cancer have low survival rates: Results of a mono-in-stitutional retrospective analysis

Sanpaolo P, Barbieri V, Genovesi D, Fu-sco V, Ausilicefaro G, Audisio, R.Patients younger than 40years old and older than 70years old affected by ER(-)/PR(-)/HER2(-) breast cancer have low survival rates: Results of a mono-institutional retrospective analysis. J Geriatr Oncol. 2012; 3 (4):312-319. doi: 10.1016/j.jgo.2012.06.001.

1,00 0,50

3 15

Prostate cancer in magnetic resonance imaging: diagnostic utilities of spectroscopic sequences

Caivano R, Cirillo P, Balestra A, Lotumolo A, Fortunato G, Macarini L,Zandolino A, Vita G, Cammarota A. Prostate cancer in magnetic resonance imaging: diagnostic utilities of spectro-scopic sequences. J Med Imaging Radiat Oncol. 2012 Dec;56(6):606-16. doi: 10.1111/j.1754-9485.2012.02449.x. Epub 2012 Sep 25. PubMed PMID: 23210579.

0,87 1,00

3 16

Radiotherapy and beva-cizumab for intramedul-lary and leptomenigeal metastatic glioblastoma: A case report and re-view of the literature

Fiorentino A, Caivano R, Chiumento C, Cozzolino M, Fusco V. Radiotherapy andbevacizumab for intramedullary and leptomenigeal metastatic glioblastoma: a case report and review of the literature. Int J Neurosci. 2012 Nov;122(11):691-4. doi: 10.3109/00207454.2012.704456. Epub 2012 Aug 8. Review. PubMed PMID: 22720749.

0,97 1,00

3 17

Radiotherapy and temozolomide in ana-plastic astrocytoma: A retrospective multicen-ter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology)

Scoccianti S, Magrini SM, Ricardi U, Detti B, Krengli M, Parisi S, Bertoni F, Sotti G, Cipressi S, Tombolini V, Dall’oglio S, Lioce M, Saieva C, Buglione M, Mantovani C, Rubino G, Muto P, Fusco V, Fariselli L, de Renzis C, Masini L, Santoni R, Pirtoli L, Biti G. Radiotherapy and temozolo-mide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous Sy-stem Study Group of AIRO (Italian Association of Radiation Oncology). Neuro Oncol. 2012 Jun;14(6):798-807. doi: 10.1093/neuonc/nos081. Epub 2012 Apr 25. PubMed PMID: 22539339; PubMed Central PMCID: PMC3367850.

5,72 6,00

3 18

Technique of Whole Brain Radiotherapy: Conformity Index and Parotid Glands

Fiorentino A, Caivano R, Chiumento C, Cozzolino M, Pedicini P, Clemente S,Fusco V. Technique of whole brain radio-therapy: conformity index and parotidglands. Clin Oncol (R Coll Radiol). 2012 Nov;24(9):e140-1. doi: 10.1016/j.clon.2012.07.003. Epub 2012 Jul 25. PubMed PMID: 22841150.

2,07 1,00

3 19

The role of radiothe-rapy in adult medullo-blastoma: Long-term single-institution expe-rience and a review of the literature

Balducci M, Chiesa S, Chieffo D, Manfrida S, Dinapoli N, Fiorentino A, Miccichè F, Frascino V, Anile C, Valentini V, De Bari B. The role of radiotherapy in adult medul-loblastoma: long-term single-institution experience and a review of the literatu-re. J Neurooncol. 2012 Jan;106(2):315-23. doi: 10.1007/s11060-011-0665-7. Epub 2011 Jul 31. Review. Erratum in: J Neurooncol. 2012 Jan;106(2):325. PubMed PMID: 21805324.

3,21 3,00

3 20Whole brain radiothe-rapy: Are parotid glands organs at risk?

Fiorentino A, Chiumento C, Caivano R, Cozzolino M, Clemente S, Pedicini P,Fusco V. “Whole brain radiotherapy: are parotid glands organs at risk?”.Radiother Oncol. 2012 Apr;103(1):130-1. doi: 10.1016/j.radonc.2012.01.013. Epub 2012 Mar 3. PubMed PMID: 22385798.

5,58 3,00

3 21

3D dosimetry in pa-tients with early breast cancer undergoing In-traoperative Avidination for Radionuclide The-rapy (IART®) combi-ned with external beam radiation therapy

Ferrari ME, Cremonesi M, Di Dia A, Bot-ta F, De Cicco C, Sarnelli A, PediciniP, Calabrese M, Orecchia R, Pedroli G, Paganelli G. 3D dosimetry in patients with early breast cancer undergoing In-traoperative Avidination for RadionuclideTherapy (IART) combined with external beam radiation therapy. Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1702-11. doi: 10.1007/s00259-012-2197-6. Epub 2012 Aug 14. PubMed PMID: 22890802.

4,99 3,00

Totale Pubblicazioni n.21 66,74 56,00

Totale Pubblicazioni Istituto 2012 n. 81 398.6 282.1